Redx Pharma plc Presentation at Cowen Healthcare Conference (2637Q)

TIDMREDX

RNS Number : 2637Q

Redx Pharma plc

25 February 2021

REDX PHARMA PLC

("Redx" or "the Company" or "Redx Pharma")

Redx Pharma to present at the Cowen 41(st) Annual Health Care Conference

Alderley Park, 25 February 2021 Redx Pharma (AIM:REDX), the drug discovery and development Company focused on oncology and fibrosis, today announces that Lisa Anson, Chief Executive Officer, will give an update on progress made by the Company, at the Cowen 41st Annual Health Care Conference on Thursday 4 March, 2021 at 16:10 GMT / 11:10 EST.

A live webcast of the presentation will be available for viewing at: https://wsw.com/webcast/cowen81/redx.l/2192577

Following the event, a recording will be made available on the investor section of the Company's website at: https://www.redxpharma.com/investor-centre/presentations-analyst-reports-documents-and-videos/ .

 
  For further information, please contact: 
 
  Redx Pharma Plc                                T: +44 1625 469 
                                                  918 
  Iain Ross, Chairman 
   Lisa Anson, Chief Executive Officer 
   James Mead, Chief Financial Officer 
 
  SPARK Advisory Partners (Nominated Adviser)    T: +44 203 368 
                                                  3550 
  Matt Davis/Adam Dawes 
 
  WG Partners LLP (Broker)                       T: +44 20 3705 
                                                  9330 
  Claes Spång/Chris Lee/David Wilson 
 
 
  FTI Consulting                                 T: +44 20 3727 
                                                  1000 
  Simon Conway/Ciara Martin

About Redx Pharma Plc

Redx Pharma (AIM:REDX) is focused on the discovery and development of novel targeted medicines for the treatment of cancer and fibrotic disease, aiming to progress them to clinical Proof of Concept. Redx's lead oncology asset, RXC004, is currently in a Phase 1 study in patients with advanced malignancies with top line data expected in H1 2021 and the Company's selective ROCK2 inhibitor, RXC007, is expected to enter a Phase 1 clinical study in H1 2021.

The Company's core capability of converting medicinal chemistry insights into differentiated and commercially attractive small molecule drug candidates against clinically validated targets has been recognized by others. Over the last three years the company has completed four major preclinical stage deals with AstraZeneca, Jazz Pharmaceuticals and Loxo Oncology (now Eli Lilly).

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCEANALAEKFEFA

(END) Dow Jones Newswires

February 25, 2021 02:00 ET (07:00 GMT)

Redx Pharma (LSE:REDX)
Historical Stock Chart
From Jul 2024 to Aug 2024